课题基金 / 基金详情

PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX

PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX
Zenapax 的 I/II 期开放标签药代动力学和安全性研究
批准号：
6297763
负责人：
ROBERT Bruce ETTENGER
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297763
关键词：
acute disease /disorder chronic disease /disorder chronic renal failure clinical research clinical trial phase I dialysis therapy drug screening /evaluation homologous transplantation human subject human therapy evaluation immunosuppressive kidney transplantation pharmacokinetics transplant rejection

项目摘要

项目成果

ROBERT Bruce ETTENGER的其他基金

相关文献

中文摘要
翻译
肾移植是治疗终末期肾衰竭的首选方法。 疾病 移植排斥反应的治疗进展 增加了患者和移植物的存活率。 然而 急性和慢性排斥都继续阻碍移植物存活。 在 一年后，约80%的移植物存活，约一半存活至8年。 失败的移植物需要透析和再次移植，如果可能的话。 延长移植物存活时间，有效增加器官供应 相对于需求。
英文摘要
Kidney transplantation is the treatment of choice for end stage renal disease. Advances in the treatment of allograft rejection have increased the survival of both patients and their grafts. Nevertheless acute and chronic rejection both continue to hamper graft survival. At one year, about 80% of grafts survive about half survive to 8 years. Failed grafts require dialysis and retransplantation when possible. Prolongation of graft survival effectively increase the supply of organs relative to demand.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX